Efficacy and Safety of 4 Doses of QGE031 in Patients 18-50 Years of Age With Peanut Allergy

NCT01451450 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Peanut Allergy

Interventions

DRUG: QGE031
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals